Warning Letter — Jing Cheong Asia Inc. dba New York Tong Ren Tang
The FDA issued a warning letter to Jing Cheong Asia Inc. (dba New York Tong Ren Tang) following an evaluation by the Center for Drug Evaluation and Research (CDER).
This affects Jing Cheong Asia Inc., its subsidiary New York Tong Ren Tang, and regulatory/compliance departments responsible for product labeling and drug approvals.
The involvement of CDER suggests the FDA has identified products being marketed as unapproved new drugs or misbranded drugs. This may indicate that the company's product claims or formulations crossed the threshold from dietary supplements into regulated medicinal products without the required pre-market approvals.
Review all product labeling and website claims to ensure no unapproved drug claims are made for products marketed as supplements. Verify that all products meeting the statutory definition of a drug have an approved NDA or ANDA prior to distribution.
FDA Warning Letter issued to: Jing Cheong Asia Inc. dba New York Tong Ren Tang. 10/26/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/jing-cheong-asia-inc-dba-new-york-tong-ren-tang-738200-10262026
Open in openFDA / FDA.gov